摘要
目的:研究化疗联合放疗治疗非小细胞肺癌的临床疗效及毒副作用。方法:58例非小细胞肺癌患者随机分为观察组与对照组两组各29例,观察组患者采用化疗联合放疗治疗,对照组患者只采用化疗治疗。观察比较两组患者的临床疗效、1,2,3年生存率及毒副作用。结果:观察组患者的有效率(79.3%)明显高于对照组(41.4%),两组相比差异有统计学意义(P<0.05)。观察组患者1,2,3年生存率均高于对照组,两组相比差异有统计学意义(P<0.05,P<0.01)。两组患者的Ⅲ-Ⅳ级白细胞减少率,Ⅲ-Ⅳ级血红蛋白减少率,Ⅲ-Ⅳ级消化系统反应无显著差别,两组相比差异均无统计学意义(P>0.05)。结论:相对于单纯化疗,化疗联合放疗治疗非小细胞肺癌临床效果更好,毒副作用并未加重,可以显著提高患者生存率,值得临床推广应用。
Objective： To evaluate the clinical effect and toxicity of radiotherapy and chemotherapy for non-small cell lung cancer （NSCLC）. Methods： 58 patients with NSCLC were divided into two groups： concurrent chemo-radiothempy （Observation group, 29 patients） and chemotherapy only （Control group,29 patients）. Observed the clinical efficacy, 1 -, 2 - and 3-year survival rate and side effects of the two groups of patients. Results： The efficiency of observation group （79.3%） was significantly higher than control groups （41.4%）, the difference was statistically significant（P〈0.05）. Observation group with 1 -, 2 - and 3-year survival rate were higher than the control group （P〈0.05, P〈0.01）. Compared to the two groups of patients with grade HI - IV leukopenia rate, with grade Ⅲ-Ⅳ hemoglobin reduction rate and grade Ⅲ-Ⅳ digestive reaction, the difference was not statistically significant （P〉0.05）. Coaclusions： Compared to chemotherapy alone, chemotherapy and radiation therapy for non-small cell lung cancer has better clinical effect, can improve the survival rate of patients, and side effects did not increase, worthy of clinical application.
出处
《现代生物医学进展》
CAS
2013年第15期2908-2910,2935,共4页
Progress in Modern Biomedicine
基金
吴阶平医学基金会临床科研专项资助基金(320.6750.12205)
课题名称:EGFR-TKI治疗耐药后T790M突变的晚期NSCLC患者理想治疗模式的探讨
关键词
非小细胞肺癌
放射治疗
化学治疗
疗效
Non-small cell lung cancer
Radiotherapy
Chemotherapy
Efficacy
